Commissural alignment is especially important now, researchers explained, because TAVR is being recommended for younger patients with longer life expectancies. 

Patients with pure native AR are often excluded from clinical trials comparing TAVR and SAVR, leading to a lack of clarity when it comes to the proper treatment of this population.

Many patients still require a permanent pacemaker following TAVR. In fact, it is more common after TAVR than after surgical aortic valve replacement. 

According to a new study of more than 119,000 hospitalizations, the costs associated with TAVR are far from consistent. 

The new Boston Scientific valve received CE mark approval in 2020, but has not been approved by the FDA.

Both vendors used the four-day conference as an opportunity to provide key updates about their TAVR valves.